Vic P, Sablier G, François C, Michel H, Sentein P, Boucard M
Toxicol Eur Res. 1981 Jan;3(1):17-22.
Hepatic toxicity was observed in mice which had received Griseofulvin or Perhexilin Maleate over a period of several months. Treatment of griseofulvin alone gave rise to hepatitis with the presence of Mallory bodies (MB) whereas the same length of treatment with Perhexilin Maleate was associated with steatonecrosis with an absence of MB. When treatment was followed by a one month rest period hepatic lesions disappeared with no trace of sequelae. Cross-treatment studies showed that one week of Perhexiline Maleate was sufficient to induce MB in mice pretreated with Griseofulvin. Similarly, Griseofulvin administered to mice pretreated with Perhexilin Maleate gave rise to MB formation after one week as opposed to the usual two months incubation time (DENK et al.). The histological nature and mode of formation of these MB was identical to that encountered in acute alcoholic hepatitis. On addition, combined drug therapy employing Perhexilin Maleate suggests a particular hepatic toxicity in man in cases where the liver has become predisposed due to other therapeutic.
在连续数月接受灰黄霉素或马来酸哌克昔林治疗的小鼠中观察到肝毒性。单独使用灰黄霉素治疗会引发伴有马洛里小体(MB)的肝炎,而相同疗程的马来酸哌克昔林治疗则与脂肪坏死相关,且不存在MB。当治疗后有一个月的休息期时,肝脏病变消失,不留后遗症痕迹。交叉治疗研究表明,一周的马来酸哌克昔林足以在预先用灰黄霉素处理过的小鼠中诱导MB形成。同样,给预先用马来酸哌克昔林处理过的小鼠施用灰黄霉素,一周后会形成MB,这与通常两个月的潜伏期不同(登克等人)。这些MB的组织学性质和形成方式与急性酒精性肝炎中所见相同。此外,在肝脏因其他治疗而变得易感性增加的情况下,联合使用马来酸哌克昔林的药物治疗提示在人类中存在特定的肝毒性。